Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis

Background Pancreatitis is the most common major complication of diagnostic and therapeutic ERCP. Platelet-activating factor (PAF) has been implicated in the pathophysiologic events associated with acute pancreatitis. Animal and human studies suggested that recombinant PAF acetylhydrolase (rPAF-AH)...

Full description

Saved in:
Bibliographic Details
Published in:Gastrointestinal endoscopy 2009-03, Vol.69 (3), p.462-472
Main Authors: Sherman, Stuart, MD, Alazmi, Waleed M., MD, Lehman, Glen A., MD, Geenen, Joseph E., MD, Chuttani, Ram, MD, Kozarek, Richard A., MD, Welch, William D., PhD, Souza, Sonia, PhD, Pribble, John, PharmD
Format: Article
Language:English
Subjects:
1-Alkyl-2-acetylglycerophosphocholine Esterase - therapeutic use
Acute Disease
Aged, 80 and over
Biological and medical sciences
Cholangiopancreatography, Endoscopic Retrograde - adverse effects
Digestive system
Double-Blind Method
Female
Gastroenterology and Hepatology
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Incidence
Investigative techniques, diagnostic techniques (general aspects)
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Pancreatitis - epidemiology
Pancreatitis - etiology
Pancreatitis - prevention & control
Radiodiagnosis. Nmr imagery. Nmr spectrometry
Recombinant Proteins - therapeutic use
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Pancreatitis is the most common major complication of diagnostic and therapeutic ERCP. Platelet-activating factor (PAF) has been implicated in the pathophysiologic events associated with acute pancreatitis. Animal and human studies suggested that recombinant PAF acetylhydrolase (rPAF-AH) might ameliorate the severity of acute pancreatitis. Objective Our purpose was to determine whether prophylactic rPAF-AH administration reduces the frequency or severity of post-ERCP pancreatitis in high-risk patients. Design Randomized, multicenter, double-blind, placebo-controlled study. Interventions Patients received rPAF-AH at a dose of either 1 or 5 mg/kg or placebo. Patients were administered a single intravenous infusion over 10 minutes of study drug or placebo
ISSN:0016-5107
1097-6779
DOI:10.1016/j.gie.2008.07.040